• BioVie completed the last patient evaluation visit in its Phase 2 SUNRISE-PD trial of bezisterim in early-stage Parkinson’s disease.
• Topline results have not been presented yet; they are scheduled for release in Q3 2026.
• The trial was set up to gauge whether bezisterim can deliver clinically meaningful improvements across motor and non-motor symptoms to support the design of Phase 3 registrational studies.
• The 20-week study randomized 57 patients 1:1 to bezisterim or placebo, targeting patients not treated with carbidopa/levodopa.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioVie Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605180800PRIMZONEFULLFEED9721528) on May 18, 2026, and is solely responsible for the information contained therein.